Prevalence and Self-recognition of Chronic Constipation: Results of an Internet Survey

Tamura, Akio; Tomita, Toshihiko; Oshima, Tadayuki; Toyoshima, Fumihiko; Yamasaki, Takahisa; Okugawa, Takuya; Kondo, Takashi; Kono, Tomoaki; Tozawa, Katsuyuki; Ikehara, Hisatomo; Ohda, Yoshio; Fukui, Hirokazu; Watari, Jiro; Miwa, Hiroto

doi:10.5056/jnm15187

Cited by 73 publications

(70 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30,31 These findings suggest that alteration of the gut microbiota has potential as a new treatment target for chronic functional constipation. Given that the prevalence of chronic constipation in Japanese is 28.4%, 34 it is possible that H. pylori infection may be a risk factor for chronic constipation or symptoms of chronic constipation. 32,33 In our present study, the prevalence of H. pylori-positive patients with symptoms of chronic constipation was 48.8% in the GSRS questionnaire and 47.0% in the Izumo scale.…”

Section: -Hydroxytryptamine 4 Serotonin Receptor Agonists Bulkingmentioning

confidence: 99%

“…32,33 In our present study, the prevalence of H. pylori-positive patients with symptoms of chronic constipation was 48.8% in the GSRS questionnaire and 47.0% in the Izumo scale. Given that the prevalence of chronic constipation in Japanese is 28.4%, 34 it is possible that H. pylori infection may be a risk factor for chronic constipation or symptoms of chronic constipation. Therefore, H. pylori eradication therapy may have the potential to improve symptoms of chronic constipation.…”

Section: -Hydroxytryptamine 4 Serotonin Receptor Agonists Bulkingmentioning

confidence: 99%

See 1 more Smart Citation

Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation

et al. 2018

View full text Add to dashboard Cite

Backgrounds and Aims Constipation is one of the most common gastrointestinal functional disorders. Recently, the gut microbiota has been implicated in the development of constipation. Helicobacter pylori infection is considered to be a possible factor influencing the gut microbiota profile. Here, we investigated the effect of H. pylori eradication therapy on symptoms of chronic constipation. Methods We recruited 166 H pylori‐positive patients who underwent eradication therapy after endoscopy. We evaluated the severity of symptoms of chronic constipation before eradication therapy and 2 months post‐therapy using two questionnaires, the Gastrointestinal Symptom Rating Scale (GSRS) and the Izumo scale. In addition, we evaluated association with constipation and H. pylori infection in patients with constipation‐related symptoms in not only all patients, but also patients with the constipation‐related symptoms in relation to eradication outcome, the severity of constipation‐related symptoms, and the severity of endoscopic gastric mucosal atrophy. Results Mean GSRS scores were 5.10 ± 2.67 in all patients and 6.15 ± 2.91 in constipation patients which were significantly lower than that before eradication (5.78 ± 3.27, P < 0.01 and 8.19 ± 3.09, P < 0.01, respectively). Constipation‐related scores of the GSRS questionnaire in the successful eradication group were significantly improved after eradication from 5.63 ± 3.06 in all patients and 8.00 ± 2.85 in constipation patients to 5.11 ± 2.71 (P = 0.02) and 6.16 ± 2.96 (P < 0.01), while scores in the failed eradication group before and after eradication were similar. Constipation‐related scores in patients with mild gastric atrophy (Kimura‐Takemoto classification, C‐I to O‐I) were significantly decreased after eradication, but were not decreased in patients with severe atrophy (O‐II and O‐III). Conclusions Successful eradication therapy for H. pylori infection may confer additional benefits in H. pylori‐positive patients with symptoms of chronic constipation, especially in patients with mild gastric atrophy.

show abstract

Section: -Hydroxytryptamine 4 Serotonin Receptor Agonists Bulkingmentioning

confidence: 99%

Section: -Hydroxytryptamine 4 Serotonin Receptor Agonists Bulkingmentioning

confidence: 99%

Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Systematic reviews found a predominance of women and elderly people with CC 2, 3 and reported prevalence rates of 17.1% and 15.3% in Europe and Oceania, respectively 2. In an online survey of 5155 Japanese, 28.4% respondents self‐reported constipation 4. Constipated individuals experience a physically and mentally lower quality of life 5 and a pose to greater socioeconomic burden 6 than nonconstipated individuals.…”

Section: Introductionmentioning

confidence: 99%

Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial

Kumagai

Aoki

Sasaki

et al. 2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimsElobixibat is a minimally absorbed ileal bile acid transporter inhibitor. This study aimed to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of elobixibat in Japanese patients with chronic constipation.MethodsThis study consisted of single‐dose and multiple‐dose tests with a dose‐escalating design. Sixty patients including females and males were randomized into five dose levels of elobixibat (2.5, 5, 10, 15 or 20 mg, n = 10 per level) and corresponding placebo (n = 2 per group). A crossover design was used to examine food effect in single‐dose test. Patients received test tablets once daily for 14 days in multiple‐dose test. We assessed pharmacokinetic‐dose proportionality, levels of serum high‐ and low‐density lipoprotein cholesterol and plasma 7α‐hydroxy‐4‐cholesten‐3‐one (C4), food effect and sex‐specific effect. Adverse events and bowel functions such as bowel movements, stool consistency and straining were also evaluated.ResultsFood consumption reduced systemic exposure by around 80% [e.g. least squares mean (ratio of breakfast/no breakfast) maximum plasma concentration: 0.2085 (90% confidence interval, 0.1371–0.3172) at 15 mg] while increased plasma C4 level (P < 0.001). In the multiple‐dose test, elobixibat reduced low‐density lipoprotein cholesterol and increased C4 whilst unaltering high‐density lipoprotein cholesterol level. The increased spontaneous bowel movement frequency was correlated with higher dosage and higher C4 level (R2 = 0.5929 at Week 2). Adverse events were mainly gastrointestinal symptoms, most of which were mild.ConclusionsElobixibat should be taken before breakfast. Once‐daily administration of elobixibat was found to be safe and tolerated up to 20 mg in female and male patients with chronic constipation.

show abstract

“…Constipation is self-reported by 27.2% of North American adults 1 and 28.4% of Japanese adults, 2 although the prevalence differs with the definition used. The symptoms of chronic constipation are infrequent bowel movements, straining, a sensation of incomplete evacuation, and the presence of hard stools.…”

Section: Introductionmentioning

confidence: 99%

Efficacy, long‐term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan

Nakajima

Taniguchi

Kurosu

et al. 2019

Neurogastroenterology Motil

View full text Add to dashboard Cite

Background In two phase 3 trials, elobixibat, a locally acting ileal bile acid transporter inhibitor, resolved constipation and was well tolerated in Japanese patients with chronic constipation. We analyzed the efficacy, safety, and impact on quality of life (QOL) of elobixibat in patients with symptomatically more severe constipation in the two phase 3 trials. Methods This post hoc analysis of elobixibat treatment outcomes included data from a 2‐week, randomized, placebo‐controlled, phase 3 trial (10 mg/d), and a 52‐week, open‐label trial (5‐15 mg/d) in subgroups with severe constipation defined as ≤2 spontaneous bowel movements (SBMs) and ≤3 Bristol Stool Form Scale score during the second week of the 2‐week run‐in period. We also analyzed the rates of abdominal pain, diarrhea, and QOL in subgroups according to sex, presence of constipation‐predominant irritable bowel syndrome (IBS‐C) and side effects. Key Results In patients with severe constipation, there was significant improvement in the 10 mg elobixibat group compared to the placebo group in change in SBMs from baseline at week 1 (primary endpoint) of the 2‐week trial. The differences between groups were reduced in patients with more severe constipation. Increasing the dose to 15 mg was effective for more severe constipation in improving the number of SBMs per week in the 52‐week trial. Overall, elobixibat was well tolerated and improved QOL scores, irrespective of gender, presence of IBS‐C or side effects. Conclusions & Inferences Elobixibat is effective for symptomatically severe constipation, is well tolerated and improves QOL, irrespective of potentially confounding patient characteristics.

show abstract

Prevalence and Self-recognition of Chronic Constipation: Results of an Internet Survey

Cited by 73 publications

References 35 publications

Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation

Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation

Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial

Efficacy, long‐term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan

Contact Info

Product

Resources

About